AQUA 23: BLOOD WORK FOR PATIENTS RECEIVING ABIRATERONE

STEWARD
AMERICAN UROLOGICAL ASSOCIATION

DESCRIPTION

Percentage of patients receiving abiraterone who receive monthly blood work and serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment and every two weeks for the first three months of treatment and monthly thereafter

TYPE
Process

DATA SOURCE
Electronic Health Records: AQUA Registry Data

NUMERATOR STATEMENT

A. Number of patients getting blood work on a monthly basis.
B. Number of patients receiving abiraterone whose serum transaminases (ALT and AST) and bilirubin levels were measured prior to starting treatment.
C. Number of patients tested for serum transaminases and bilirubin levels every two weeks during the first 3 months of treatment.
D. Number of patients receiving abiraterone whose serum transaminases (ALT and AST) and bilirubin levels were measured monthly after month 3 of treatment.
E. Overall Performance: Number of patients receiving abiraterone who receive monthly blood work and serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment and every two weeks for the first three months of treatment and monthly thereafter

DENOMINATOR STATEMENT

Patients with advanced prostate cancer on abiraterone

DENOMINATOR DETAILS

List Denominator Codes

DENOMINATOR EXCLUSIONS/EXCEPTIONs
RATIONALE

Patients on abiraterone should also receive monthly bloodwork and serum transaminases and bilirubin levels prior to treatment. Abiraterone can be associated with liver toxicity and hypokalemia. Therefore, patients are recommended to undergo monthly measurement of liver function tests, blood pressure, and potassium levels. Failure to do so may put the patient at risk for severe unknown reactions.

RISK ADJUSTMENT

No

INVERSE MEASURE

No

ALGORITHM

COPYRIGHT/DISCLAIMER

AMERICAN UROLOGICAL ASSOCIATION